ATE512986T1 - Antikörper gegen clostridium difficile-toxine und ihre verwendung - Google Patents

Antikörper gegen clostridium difficile-toxine und ihre verwendung

Info

Publication number
ATE512986T1
ATE512986T1 AT05857759T AT05857759T ATE512986T1 AT E512986 T1 ATE512986 T1 AT E512986T1 AT 05857759 T AT05857759 T AT 05857759T AT 05857759 T AT05857759 T AT 05857759T AT E512986 T1 ATE512986 T1 AT E512986T1
Authority
AT
Austria
Prior art keywords
antibodies
clostridium difficile
difficile toxins
toxins
antigen binding
Prior art date
Application number
AT05857759T
Other languages
English (en)
Inventor
Donna Ambrosino
Gregory Babcock
Theresa Broering
Robert Graziano
Hector Hernandez
Israel Lowy
Robert Mandell
Deborah Molrine
William Thomas
Hui-Fen Zhang
Original Assignee
Univ Massachusetts
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36928722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE512986(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Massachusetts, Medarex Inc filed Critical Univ Massachusetts
Application granted granted Critical
Publication of ATE512986T1 publication Critical patent/ATE512986T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
AT05857759T 2004-02-06 2005-02-04 Antikörper gegen clostridium difficile-toxine und ihre verwendung ATE512986T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54235704P 2004-02-06 2004-02-06
US61385404P 2004-09-28 2004-09-28
PCT/US2005/003725 WO2006121422A2 (en) 2004-02-06 2005-02-04 Antibodies against clostridium difficile toxins and uses thereof

Publications (1)

Publication Number Publication Date
ATE512986T1 true ATE512986T1 (de) 2011-07-15

Family

ID=36928722

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05857759T ATE512986T1 (de) 2004-02-06 2005-02-04 Antikörper gegen clostridium difficile-toxine und ihre verwendung

Country Status (26)

Country Link
US (8) US7625559B2 (de)
EP (3) EP2857418B1 (de)
JP (3) JP4588763B2 (de)
KR (3) KR101332927B1 (de)
CN (1) CN101014620B (de)
AT (1) ATE512986T1 (de)
AU (1) AU2005320349C1 (de)
BR (1) BRPI0507433C1 (de)
CA (1) CA2553946C (de)
CY (3) CY1111860T1 (de)
DK (3) DK2270045T3 (de)
ES (3) ES2533492T3 (de)
HK (3) HK1102287A1 (de)
HR (1) HRP20110599T1 (de)
HU (3) HUE024962T2 (de)
LT (2) LT2857418T (de)
LU (1) LUC00025I2 (de)
MX (1) MXPA06008839A (de)
NO (2) NO340300B1 (de)
NZ (2) NZ580828A (de)
PL (3) PL2857418T3 (de)
PT (3) PT2857418T (de)
RS (1) RS51908B (de)
SI (3) SI2857418T1 (de)
WO (1) WO2006121422A2 (de)
ZA (1) ZA200606516B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ES2533492T3 (es) 2004-02-06 2015-04-10 University Of Massachusetts Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos
AU2005257527B9 (en) * 2004-06-28 2009-03-05 Japan Science And Technology Agency Method of screening toxin-neutralizing peptide, STX2 inhibitory peptide and vero toxin-neutralizing agent
EP1833510A4 (de) * 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva Oral verabreichbare und anti-toxin-antikörper und herstellungs- und anwendungsverfahren dafür
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
AU2014201846B2 (en) * 2007-01-30 2016-07-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US7884184B2 (en) 2007-01-30 2011-02-08 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
US20080188007A1 (en) * 2007-02-06 2008-08-07 Meridian Life Science, Inc. Fluorescent single chain antibody and its use in detection of analytes
CN101363867B (zh) * 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
WO2009154995A2 (en) * 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
WO2011012098A1 (de) * 2009-07-27 2011-02-03 Tgcbiomics Gmbh Verfahren zum nachweis und zur identifikation eines varianten c. difficile stammes in einer probe
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
WO2011063346A1 (en) * 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
KR101820987B1 (ko) * 2010-04-15 2018-01-22 프로제닉스 파머슈티컬스, 인코포레이티드 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체
RU2630663C9 (ru) * 2010-04-15 2017-11-29 Проджиникс Фармасьютикалс, Инк. Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
DK2753352T4 (da) 2010-09-03 2022-09-12 Valneva Austria Gmbh Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
WO2012055030A1 (en) * 2010-10-25 2012-05-03 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CN103608464A (zh) * 2010-12-29 2014-02-26 卡恩基因公司 艰难梭菌抗原
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
SI2699587T1 (sl) * 2011-04-22 2019-08-30 Wyeth Llc Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka
EP2741785B1 (de) * 2011-07-12 2018-09-05 Philadelphia Health and Education Corporation Neuer clostridium-difficile-dna-impfstoff
CA2845884A1 (en) * 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
MX2014002769A (es) * 2011-09-16 2014-06-11 Ucb Pharma Sa Anticuerpos neutralizantes para las exotoxinas principales tcda y tcdb de clostridium difficile.
CA2856085C (en) 2011-11-18 2020-06-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
RU2014127714A (ru) 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
RU2628305C2 (ru) 2012-03-02 2017-08-15 Регенерон Фармасьютиказ, Инк. Человеческие антитела к токсинам clostridium difficile
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
EP2921502A4 (de) * 2012-10-19 2016-09-28 Evec Inc Gegen toxin aus clostridium difficile oder antigenbindendem fragment spezifischer menschlicher antikörper
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CA2892973A1 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
WO2014144292A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
CA2909636C (en) * 2013-04-19 2023-08-22 Dena Lyras Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
WO2015100409A2 (en) * 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
CN105992772A (zh) * 2014-02-10 2016-10-05 Igm生命科学股份有限公司 IgA多特异性结合分子
EP3107567A4 (de) 2014-02-19 2017-10-25 Cangene Corporation Verfahren zur modulierung einer immunreaktion
WO2015157629A2 (en) 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
WO2015184454A1 (en) * 2014-05-30 2015-12-03 Case Western Reserve University Clostridium difficile culture medium
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (de) 2014-06-20 2019-04-17 Immunimed Inc. Polyklonale antikörper gegen clostridium difficile und ihre verwendung
WO2016131157A1 (en) * 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
EP3277706A1 (de) 2015-03-31 2018-02-07 VHsquared Limited Polypeptid mit immunglobulinkettenvariabler domäne mit bindung an clostridium-difficile-toxin b
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
CN105039262B (zh) * 2015-07-10 2018-07-03 北京科兴中维生物技术有限公司 破伤风类毒素单克隆抗体及其应用
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
SG11201804787UA (en) 2015-12-15 2018-07-30 Gilead Sciences Inc Human immunodeficiency virus neutralizing antibodies
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018035407A1 (en) * 2016-08-19 2018-02-22 Enbiotix, Inc. Bacteriophages for neutralizing toxins and methods of use thereof
CN110831965B (zh) 2017-06-21 2023-03-07 吉利德科学公司 靶向hiv gp120和cd3的多特异性抗体
JP7347849B2 (ja) * 2018-04-19 2023-09-20 ファースト ライト ダイアグノスティクス， インコーポレイテッド 標的の検出
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
WO2021219786A1 (en) * 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
CN111499738B (zh) * 2020-06-03 2022-04-05 郑州师范学院 一种抗艰难梭菌肠毒素a的抗体
CN114853895B (zh) * 2020-11-30 2023-05-09 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用
CN117720651A (zh) * 2023-12-13 2024-03-19 北京新兴四寰生物技术有限公司 抗艰难梭菌毒素b的单克隆抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (de) 1991-05-17 2005-02-23 Merck & Co. Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
CA2125396A1 (en) * 1991-12-10 1993-06-24 Wayne A. Marasco Reactive neutralizing human anti-gp 120 recombinant antibody, dna coding the same and use thereof
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE69535530D1 (de) 1994-10-24 2007-08-16 Ophidian Pharm Inc Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP2305303A3 (de) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunisierung gegen Clostridium difficile-Erkrankung
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP2829609A1 (de) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Humane Antikörper gegen CTLA-4-Antikörper und Verwendungen davon
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP3190126A1 (de) 2000-05-26 2017-07-12 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
AU2003224604B2 (en) * 2002-01-28 2007-06-14 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
ATE475431T1 (de) * 2002-03-04 2010-08-15 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
PT1490405E (pt) * 2002-03-21 2007-11-07 Lilly Co Eli Anticorpos humanos anti-ligando de hfas antagonistas e fragmentos dos mesmos
CA2484930A1 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
AU2003298816C1 (en) * 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
CA2507924A1 (en) 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20070003561A1 (en) * 2003-07-08 2007-01-04 Sorensen Anders P Binding member towards pneumococcus surface adhesin a protein (psaa)
PL1691837T3 (pl) * 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
ES2533492T3 (es) 2004-02-06 2015-04-10 University Of Massachusetts Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
JP5319622B2 (ja) 2013-10-16
US7625559B2 (en) 2009-12-01
ES2533492T3 (es) 2015-04-10
EP2857418A1 (de) 2015-04-08
SI2857418T1 (en) 2018-01-31
CY2017022I2 (el) 2017-11-14
US20210269511A1 (en) 2021-09-02
LTC2270045I2 (lt) 2019-12-10
BRPI0507433A (pt) 2007-07-03
US8257709B2 (en) 2012-09-04
BRPI0507433B8 (pt) 2018-04-10
EP2857418B1 (de) 2017-07-26
DK1766093T3 (da) 2011-10-03
US20050287150A1 (en) 2005-12-29
HUE034552T2 (en) 2018-02-28
ZA200606516B (en) 2011-01-26
US20140120614A1 (en) 2014-05-01
RS51908B (en) 2012-02-29
PL2270045T3 (pl) 2015-06-30
SI1766093T1 (sl) 2011-12-30
EP1766093B1 (de) 2011-06-15
HUE024962T2 (en) 2016-02-29
KR20120003017A (ko) 2012-01-09
KR101332994B1 (ko) 2013-11-26
JP2007533330A (ja) 2007-11-22
SI2270045T1 (sl) 2015-06-30
EP2270045B8 (de) 2015-02-25
DK2857418T3 (en) 2017-10-23
PT1766093E (pt) 2011-08-24
NO20063767L (no) 2006-10-02
CA2553946A1 (en) 2005-08-06
CN101014620A (zh) 2007-08-08
AU2005320349B8 (en) 2010-04-22
US8236311B2 (en) 2012-08-07
LUC00025I1 (de) 2017-07-06
WO2006121422A3 (en) 2007-03-15
BRPI0507433B1 (pt) 2018-03-20
KR101332927B1 (ko) 2013-11-26
HUS1700028I1 (hu) 2017-07-28
HK1102287A1 (en) 2007-11-09
NO2017032I1 (no) 2017-07-07
AU2005320349A8 (en) 2008-08-07
LT2857418T (lt) 2017-09-25
KR20070050863A (ko) 2007-05-16
CA2553946C (en) 2019-02-26
AU2005320349C1 (en) 2019-06-13
EP2270045B1 (de) 2014-12-31
NZ580828A (en) 2011-09-30
JP4588763B2 (ja) 2010-12-01
NZ548821A (en) 2009-12-24
EP2270045A1 (de) 2011-01-05
MXPA06008839A (es) 2008-03-07
PL2857418T3 (pl) 2017-10-31
LUC00025I2 (de) 2017-09-08
US20100233182A1 (en) 2010-09-16
PT2857418T (pt) 2017-10-20
AU2005320349A1 (en) 2006-08-24
CN101014620B (zh) 2012-05-09
EP1766093A2 (de) 2007-03-28
PT2270045E (pt) 2015-04-08
US20180208643A1 (en) 2018-07-26
US20160152694A1 (en) 2016-06-02
HK1208873A1 (en) 2016-03-18
NO340300B1 (no) 2017-03-27
WO2006121422A8 (en) 2007-04-26
ES2643760T3 (es) 2017-11-24
BRPI0507433C1 (pt) 2021-05-25
DK2270045T3 (en) 2015-04-07
JP5717300B2 (ja) 2015-05-13
CY1119416T1 (el) 2018-03-07
LTPA2017022I1 (lt) 2017-09-11
HRP20110599T1 (hr) 2011-10-31
ES2366626T3 (es) 2011-10-24
US20120288508A1 (en) 2012-11-15
JP2013153750A (ja) 2013-08-15
WO2006121422A2 (en) 2006-11-16
US8609111B2 (en) 2013-12-17
JP2011019516A (ja) 2011-02-03
KR20120083534A (ko) 2012-07-25
US20100233181A1 (en) 2010-09-16
PL1766093T3 (pl) 2011-11-30
AU2005320349B2 (en) 2010-04-08
HK1152048A1 (en) 2012-02-17
CY1111860T1 (el) 2015-11-04
CY2017022I1 (el) 2017-11-14
US9217029B2 (en) 2015-12-22

Similar Documents

Publication Publication Date Title
ATE512986T1 (de) Antikörper gegen clostridium difficile-toxine und ihre verwendung
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
MY163480A (en) Sclerostin binding agents
ATE485307T1 (de) Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
MX2007004247A (es) Agentes de aglutinacion especifica a angiopoyetina-2.
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
WO2006118772A3 (en) Fcrn antibodies and uses thereof
WO2006119062A3 (en) Sclerostin epitopes
CY1112342T1 (el) Χιμαιρικα, υβριδικα και διαδοχικα πολυπεπτιδια μηνιγγοκοκκικου νμβ1870
DK1742966T3 (da) Antistoffer og molekyler afledt deraf som binder til STEAP-1 proteiner
DK1699826T3 (da) Syntetiske immunoglobulindomæner med bindende egenskaber konstrueret i regioner af molekylet forskellig fra de komplementaritets-bestemmende domæner
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
DE60224346D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
WO2006116319A3 (en) Reagents that bind ccx-ckr2
WO2006136892A3 (de) Neuartige cherlasky - fusionsproteine enthalten antikorperbindeproteine oder ihre regionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1766093

Country of ref document: EP